Tissue Reinforcement for Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE)

W.L. Gore & Associates

Status

Not yet enrolling

Conditions

Breast Reconstruction Surgery

Treatments

Device: TRBR Device

Study type

Interventional

Funder types

Industry

Identifiers

NCT06556654

TBR 22-07

Details and patient eligibility

About

The GORE Tissue Reinforcement for Breast Reconstruction (TRBR) research study will look at breast reconstruction during mastectomy procedures. There will be two arms in this study, a Prospective Arm, where data will be collected for a new medical device called the Tissue Reinforcement for Breast Reconstruction (TRBR) Device and a Retrospective Arm where data will be collected from subjects who have previously had surgery and received no additional tissue reinforcement in their breast reconstruction surgery. This research study will look at the safety of the Study Device and the success of the participants breast reconstruction. The Study Device is investigational, which means it has not yet been used nor approved by the FDA for this treatment. The data collected in this study will be compared to the data collected in the Retrospective Arm.

Enrollment

180 estimated patients

Sex

Female

Ages

22+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Female subjects ≥ 22 years of age.
First-time breast reconstruction post-mastectomy for target breast(s).
Scheduled to undergo unilateral or bilateral mastectomy with immediate, two-stage, implant-based, subpectoral or prepectoral breast reconstruction after mastectomy.
Mastectomy performed to address breast cancer or for cancer prophylaxis.
An informed consent form is signed by Subject or Legally Authorized Representative (LAR).
Subject is capable of following protocol procedures and complying with follow-up visit requirements

Exclusion criteria

Baseline Exclusion Criteria

Subject has had a revision(s) in the target breast(s) following complications of breast augmentation, mastopexy (breast lift), or breast reduction.
Subject has undergone previous radiation therapy to the reconstruction site or chest wall.
Subject has had chemotherapy within 3 weeks prior to the index procedure.
Subject has been treated for a systemic infection or local infection at the surgical site within 30 days prior to index procedure.
Subject has a current or previous diagnosis of Methicillin-resistant Staphylococcus aureus (MRSA).
Subject has a BMI > 35.
Subject has a known diagnosis of diabetes with a HbA1c > 7.0mmol/L within 30 days of the Index procedure (i.e., TE placement).
Subject is a current or former smoker, within 90 days prior to index procedure.
Subject is currently taking medication (e.g., systemic steroid), which in the investigator's opinion, may increase the risk of local complications of breast reconstruction.
Subject has other medical, social, or psychological conditions which could interfere with provision of informed consent, completion of tests, therapy, or follow-up.
Subject is currently participating in or planning to participate in another investigational drug, biologic or medical device study that may interfere with compliance of TBR 22-07 study requirements or may confound TBR 22-07 study data/outcomes.
Subject requires a surgical technique requiring flap (autologous tissue).
Subject is pregnant or lactating at the time of the index procedure (i.e., TE placement) or is planning to become pregnant prior to the Exchange procedure. Intraoperative Index Procedure Exclusion
Based on investigator's opinion, subject has unsuitable tissue integrity for immediate 2-stage breast reconstruction or is no longer a candidate to receive the TRBR Device (will be recorded as a screen failure).
Subject receives an Acellular Dermal Matrix (ADM) or mesh that is not the TRBR Device in the target breast(s)